		United S	Commissioner for Patents, tates Patent and Tradema. Washington, D.	k Office
U.S. APPLICATION NO.	FIRST NAMED APPLICANT	1	ATTY. DOCKET NO.	natio dos
09/673958	NANBA	N	2519USOP	-
		INTERNATIONAL	APPLICATION NO.] }
TAKEDA PHARMACEUTICALS NOF INTELLECTUAL PROPERTY DEPAR 475 HALF DAY ROAD		PCT/JF	99/02224	
SUITE 500		1.A. FILING DATE	PRIORITY DATE	
LINCOLNSHIRE, IL 60069	•	27 APR 99	28 APR 98	
		DATE MAILED:	11 JUL	2001
NOTIFIC	ATION OF A DEFECTIVE	ERESPONSE		•
1. The request for an exter	nsion of time (37 CFR 1.136)	(a)) filed	is defective	Ė
because the required fee is missing. (a)(5).	/insufficient. Extension of tir	ne fees are listed at	37 CFR 1.17(a)(1)-
2. Applicant's response fil		ved in the Office aft	er the expiration o	f
the period for response set in the O	ffice notification mailed		. This	
application will become abandoned Office notification under 37 CFR 1	unless applicant obtains an e136(a).	xtension of time to	eply to the last	
3. Applicant's response fil	ed 21 MAR 2001 is hereb	y acknowledged. T	he following	
requirements set forth in the NOTII				
	MAY 2001 have not beer	- ,	•	
Translation. Processing fee (37 CFR 1.4)	or the reasons indicated on the att 92(f)).	ached Notice of Defect	ive	
Oath or Declaration of inver	vith 37 CFR 1.497(a) and (b) for t	ha rassans indicated on	thá attachad	
PCT/DO/EO/917.	101 37 CFK 1.497(a) and (b) for t	ne reasons muicated on	me attached	
Surcharge (37 CFR 1.492(e))).			
Sequence Listing.		·.		
not in compliance w PCT/DO/EO/920.	ith 37 CFR 1.821-1.825 for the re	easons indicated on the	attached	
Additional claim fees.	· .			
/				
				•
Applicant is required to complete th his Notification or within the time in Requirements (Form DO/EO/905), granted under 37 C.F.R. § 1.136, b Requirements (Form DO/EO/905) in	remaining in the response set whichever is the longer. No ut the period for response set	forth in the Notifica extension of this tin in the Notification	tion of Missing ne limit may be	
Applicant is reminded that any common that applicant is reminded that any common that the common that applicant is reminded that any common that applicant is reminded that any common that are the common tha				•
Enclosed: PCT/DO/EO/917	Notice of Defective Translat	ion	_ 4	
PCT/DO/EO/920	•	anti	John	ion
	A	nita D. Johnson	The man	

Telephone: 703-305-3661

FORM PCT/DO/EO/916 (March 2001)



UNITED STATES DEPA Patent and Trademark O Address: ASSISTANT COMMISSION Washington, D.C. 20231

ENT OF COMMERCE

' FOR PATENTS

U.S. APPLICATION NO.	FIRST NA	MED APPLICANT	ATTY. DOCKET NO.	
09/673958	NANBA	N INTERNATIO	2519USOP TATIONAL APPLICATION NO.	
TAKEDA PHARMACEUTICALS AMERICA, INC INTELLECTUAL PROPERTY DEPARTMENT 475 HALF DAY ROAD		PCT/JP99/02224		
SUITE 500	•	I.A. FTUNG DATE	PRIORITY DATE	
LINCOLNSHIRE, IL 60069		27 APR 99	28 APR 98	
	-	DATE MAILED:	1 JUL 2001	

This application fails to contain an oath or declaration acceptable under 35 U.S.C. 371 (c)(4) for entry into the national stage in the United States of America. The period within which to correct these requirements and avoid abandonment is set in the accompanying Office action. A new oath or declaration, identifying this application by the international application number and international filing date is required. The oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it: 1. X is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68. 2. does not identify the specification to which it is directed. 3. does not identify the inventor(s). 4. does not identify the citizenship of each inventor. 5. does not state the person making the oath or declaration believes the named inventor or inventors to be the original and first inventor or inventors of the subject matter which is claimed and for which a patent is sought. FAILURE TO SUBMIT AN OATH OR DECLARATION IN COMPLIANCE WITH 37 CFR 1.497(a) AND (b) WITHIN THE TIME PERIOD SET WILL RESULT IN FAILURE TO ENTER THE NATIONAL STAGE AND THE ABANDONMENT OF THE APPLICATION. Additionally, the oath or declaration does not comply with 37 CFR 1.63 in that it: 1. does not identify the city and state or city and foreign country of residence or each inventor. 2. does not state that the person making the oath or declaration: a. has reviewed and understands the contents of the specification, including the claims, as amended by any amendment specifically referred to in the oath or declaration. b. acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56. 3. does not identify the foreign application for patent or inventor's certificate on which priority is claimed pursuant to 37 CFR 1.55, and any foreign application having a filing date before that of the application on which priority is claimed, by specifying the application serial number, country, day, month, and year of its filing. 4. Udoes not state that the person making the oath or declaration acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and filing date of the continuation in part application which discloses and claims subject matter in addition to that disclosed in the prior application (37 CFR 1.63(d)). Anita D. Johnson Telephone: 703-305-3661 EACH INVENTORS NAME MUST Appear on EACH declaration FORM PCT/DO/EO/917 (September 1996)